TY - CHAP M1 - Book, Section TI - Clopidogrel Pharmacogenomics A1 - Chyou, Janice Y. A1 - Sabatine, Marc S. A2 - Murray, Michael F. A2 - Babyatsky, Mark W. A2 - Giovanni, Monica A. A2 - Alkuraya, Fowzan S. A2 - Stewart, Douglas R. PY - 2014 T2 - Clinical Genomics: Practical Applications in Adult Patient Care AB - Drug summary:Clopidogrel blocks the P2Y12 adenosine diphosphate (ADP) receptor on the surface of platelets and thus inhibits platelet activation.Despite established clinical efficacy, an inadequate response to clopidogrel has been observed in up to 30% of compliant patients. Such variability has been labeled as “clopidogrel nonresponsiveness,” “clopidogrel hyporesponsiveness,” and “clopidogrel resistance.” SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/10/06 UR - accessmedicine.mhmedical.com/content.aspx?aid=1102698579 ER -